Drug Pricing
Our work in Drug Pricing
-
Valuing Cures Still Elusive According to Policymakers, Experts at DC Conference
Experts discussed the tensions of ensuring access for drugs while maintaining incentives for innovative cures at the conference.
-
Outcomes-Based Pricing as a Tool to Ensure Access to Novel but Expensive Biopharmaceuticals
Without new pricing models, insurers and manufacturers will remain at odds about reimbursement, leaving physicians and patients stuck in the middle.
Categorized in -
The Future of Cures: Investing in Value, Innovation and Access
High-cost drugs can generate even higher societal value when they combat serious disease, which should be accounted for in financing methods and pricing models to encourage medical innovation.
Categorized in -
MA14.09 Demonstrating Life Expectancy Gains with Immuno-Oncology (IO) Therapies
This study investigated the impact of immuno-oncology therapies on life extension of patients with non-small cell lung cancer.
Categorized in -
The Insurance Value of Medical Innovation
This study aims to show that medical innovations worth buying reduce overall risk and generate positive insurance value on its own, with calculations suggesting that conventional methods meaningfully understate the value of historical health gains and disproportionately undervalue treatments for the most severe illnesses, where physical risk to consumers is the costliest.
Categorized in -
The Role of Imperfect Surrogate Endpoint Information in Drug Approval and Reimbursement Decisions
The researchers developed an economic framework to address the value of improvement in the predictive power or quality of surrogate endpoints, which aim to predict clinical benefits, and clarify how quality can influence decisions by regulators, payers, and manufacturers.
Categorized in -
Why Academics Consulting with Industry on Health Care May be an Idea Whose Time has Come
At a time of deep political division, an academic approach to policy making has never been more important.
Categorized in -
Election Verdict: Pharma Needs a New Prescription
The pharma industry will need to get behind policy solutions that lower prices and improve access for patients today without discouraging investments into tomorrow’s valuable medical innovations.
Categorized in -
Innovation in Heart Failure Treatment: Lengthening Lives and Narrowing Disparities
Despite recent gains in medical innovation and evidence-based treatment of heart failure and associated risk factors, the incidence of heart failure is expected to double among 65- to 75- year olds by 2030 according to a new analysis by Schaeffer Center researchers.
Categorized in -
Regulate Generics Like Utilities, Goldman Urges Panel
Schaeffer Center director testifies before California Senate Committee on Health.